statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on SCYNEXIS (SCYX Research Report) today and set a price target of $7.50...

Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of...

SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Scynexis reports FY23 EPS $1.39, consensus $1.42

SCY-247's IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES...

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

With a price-to-sales (or "P/S") ratio of 0.6x SCYNEXIS, Inc. ( NASDAQ:SCYX ) may be sending very bullish signals at...

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...

SCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology Conference

In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisCombination of SCY-247 and...

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been...

SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! Final SCYX Investor...

Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

LOS ANGELES, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...

DEADLINE ALERT for SCYX, LICY, and FMC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Volume	173,113.00
52-Wk High	$3.87
52-Wk Low	$1.35

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.18	--	--	N/A
Q4'23	$0.08	-$0.32	-526.67%	MISSED
Q3'23	-$0.13	-$0.04	70.15%	BEAT
Q2'23	$1.45	$2.46	69.42%	BEAT
Q1'23	-$0.35	-$0.71	-102.86%	MISSED

SCYX Scynexis Inc

About

Feed

News

Sentiment

Earnings

Fundamentals